Abstract
Highly active antiretroviral therapy (HAART) dramatically increases the long-term survival rates of human immunodeficiency virus type 1 (HIV-1) infected patients. Yet, poor adherence to therapy, adverse effects and the occurrence of resistant viruses can compromise the efficacy of HAART regiments. Therefore, there remains a clear unmet medical need for novel drugs and treatment options. In this chapter, we describe an HIV-1 antiviral high-throughput screening assay based on an HIV-1 permissive T lymphoblastoid MT4 cell line, stably transfected with a construct carrying an HIV-1 long terminal repeat promoter driving the expression of a reporter gene (enhanced green fluorescent protein). This assay runs in a 384-well format and enables the identification of HIV-1 inhibitors during a high-throughput screening campaign. In parallel, a cytotoxicity assay is performed to evaluate the compound-related in vitro toxicity.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Pomerantz RJ, Horn DL (2003) Twenty years of therapy for HIV-1 infection. Nat Med 9:867–873
Westby M, Nakayama GR, Butler SL et al (2005) Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res 67:121–140
Pauwels R, Balzarini J, Baba M et al (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309–321
Pannecouque C, Daelemans D, De Clercq E (2008) Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 3:427–434
Pauwels R, Andries K, Debyser Z et al (1992) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alfa-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 90:1711–1715
Naylor LH (1999) Reporter gene technology: the future looks bright. Biochem Pharmacol 58:749–757
Dirk Jochmans D, Deval J, Kesteleyn B et al (2006) Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J Virol 80:12283–12292
Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Geluykens, P., Van Acker, K., Vingerhoets, J., Van den Eynde, C., Van Loock, M., Dams, G. (2013). A Fluorescence-Based High-Throughput Screening Assay to Identify HIV-1 Inhibitors. In: Gong, E. (eds) Antiviral Methods and Protocols. Methods in Molecular Biology, vol 1030. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-484-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-484-5_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-483-8
Online ISBN: 978-1-62703-484-5
eBook Packages: Springer Protocols